

850M People live with Chronic Kidney Disease



The 8th leading cause of death in the US


There is no patient-friendly treatment in the market for CKD.



For patients with advanced kidney failure, dialysis is the standard treatment, but it is costly, resource intensive, time consuming, and significantly reduces quality of life.

Market

TheraT will initially enter the nutraceutical market as a first step, with the long-term opportunity to expand into therapeutic kidney care and disrupt the dialysis market, representing an opportunity over \$100B globally.



Team



Nicolas Picon
MBA Candidate



Pei-Hsin Wang
PhD Candidate



Ming-Che Chung
PhD Candidate



Mari Winkler
Technology Lead and UW Professor

Advisors



Wendy Garrett
Harvard T.H. Chan School of Public Health
Physician and Pre-Clinical Model Expert



Jonathan Himmelfarb
Icahn School of Medicine at Mount Sinai
Nephrologist and Clinical Trial Expert




Ivan Liachko
Phase Genomics
Experienced Startup Entrepreneur



Glenda V. Roberts
Patient Advocate

Drinkable Therapy.




Hydrogel Beads capture uremic toxins in the gut, preventing them from entering the bloodstream

- Administrable anywhere
- Do not require blood access
- We can package them with a liquid in the form of “bubble tea”



Scalable Delivery Technology

- pH-responsive hydrogel beads enable targeted activity in the gut
- Microbes and binders capture multiple toxins
- Beads exit body intact, supporting safety and repeat dosing




Intellectual Property.

Patents: PCT/US2024/034373, 63/572619

Preclinical Proof of Efficacy.

In validated mouse models of kidney disease, TheraT demonstrated significant reductions in serum phosphate and multiple uremic toxins, supporting its therapeutic potential.



Competitive Landscape

	Accessibility	Cost	Quality of Life	Side Effects	Phosphate Removal	Urea Removal	PBUT Removal	Resource Intensive
THERA T	Effective	Effective	Effective	Effective	Effective	Effective	Effective	Effective
Dialysis	Partially Effective	Non-Effective	Non-Effective	Effective	Non-Effective	Effective	Non-Effective	Non-Effective
Transplant	Non-Effective	Non-Effective	Effective	Partially Effective	Effective	Effective	Effective	Partially Effective
AST-120	Effective	Effective	Effective	Partially Effective	Non-Effective	Partially Effective	Non-Effective	Effective
Renadyl	Effective	Effective	Effective	Effective	Non-Effective	Non-Effective	Partially Effective	Effective
Phosphate Binders	Effective	Effective	Effective	Partially Effective	Effective	Non-Effective	Non-Effective	Effective

Go To Market

- Phase 1 (Year 1+)** - concierge Medicine, Wellness, and Longevity markets to establish early revenue.
- Phase 2 (Year 2-7)** - Physician Sponsored Trials and execute clinical trials.
- Phase 3 (Year 7+)** - FDA approval and get insurance reimbursement approval.